NextBioMedical Publishes Study on Nexpowder in International Academic Journal

A study on 'Nexpowder', NextBioMedical's endoscopic wound covering material, has been published in an international academic journal.

According to NextBioMedical on August 4, the results of a study analyzing the effects of Nexpowder on the occurrence of post-endoscopic coagulation syndrome (PECS) after colorectal endoscopic submucosal dissection (ESD) have been published in the international journal 'Journal of Gastroenterology and Hepatology'. Post-endoscopic coagulation syndrome is a complication that can occur after ESD for colorectal polyps or colorectal cancer, in which the mucosa is removed, resulting in abdominal pain, fever, and elevated inflammatory markers.

The recently published paper is titled 'Efficacy of Nexpowder for Reducing Post-Endoscopic Coagulation Syndrome After ESD in Proximal Colonic Lesions: A Multicenter Retrospective Study.' This retrospective multicenter study was conducted in Korea and targeted patients who underwent colorectal ESD for lesions classified as high-risk for PECS. A total of 75 patients were included, with 35 (46.7%) treated with Nexpowder and 40 (53.3%) assigned to a control group. In this study, PECS was defined as cases in which post-procedural abdominal pain, fever, and raised inflammatory markers requiring antibiotic treatment occurred.

The results showed that out of all participants, 9 developed PECS. The incidence of PECS in the Nexpowder group was 2.9%, which was significantly lower than the 20.0% observed in the control group. The authors concluded, "Application of Nexpowder provides a physical barrier that covers the mucosal defect after ESD and protects the tissue, offering new clinical evidence that it can reduce the incidence of PECS."

A NextBioMedical representative stated, "This publication in an international journal is meaningful as it adds to the clinical evidence for the use and applicability of Nexpowder after colorectal ESD, following the prospective RCT study presented at Digestive Disease Week (DDW) 2026 in the U.S." They continued, "We plan to continue accumulating various forms of clinical evidence for Nexpowder based on diverse research designs in the future."

This content was produced with the assistance of AI translation services.